1. Home
  2. TWST vs HAE Comparison

TWST vs HAE Comparison

Compare TWST & HAE Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Twist Bioscience Corporation

TWST

Twist Bioscience Corporation

HOLD

Current Price

$68.31

Market Cap

3.0B

Sector

Health Care

ML Signal

HOLD

Logo Haemonetics Corporation

HAE

Haemonetics Corporation

HOLD

Current Price

$78.79

Market Cap

2.8B

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
TWST
HAE
Founded
2013
1971
Country
United States
United States
Employees
N/A
N/A
Industry
Biotechnology: Biological Products (No Diagnostic Substances)
Medical/Dental Instruments
Sector
Health Care
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
3.0B
2.8B
IPO Year
2018
1996

Fundamental Metrics

Financial Performance
Metric
TWST
HAE
Price
$68.31
$78.79
Analyst Decision
Buy
Buy
Analyst Count
8
9
Target Price
$46.88
$84.13
AVG Volume (30 Days)
1.5M
930.6K
Earning Date
05-04-2026
05-07-2026
Dividend Yield
N/A
N/A
EPS Growth
63.89
N/A
EPS
N/A
2.05
Revenue
$376,572,000.00
$910,373,000.00
Revenue This Year
$18.91
N/A
Revenue Next Year
$15.07
$5.23
P/E Ratio
N/A
$38.40
Revenue Growth
20.32
N/A
52 Week Low
$23.30
$47.32
52 Week High
$80.50
$87.32

Technical Indicators

Market Signals
Indicator
TWST
HAE
Relative Strength Index (RSI) 59.20 80.04
Support Level $41.85 $48.98
Resistance Level N/A $86.72
Average True Range (ATR) 5.06 2.89
MACD 0.37 1.46
Stochastic Oscillator 57.25 89.95

Price Performance

Historical Comparison
TWST
HAE

About TWST Twist Bioscience Corporation

Twist Bioscience Corp is a synthetic biology company that has developed a disruptive DNA synthesis platform to industrialize the engineering of biology. The company's proprietary semiconductor-based manufacturing process synthesizes DNA on silicon rather than traditional plastic plates, enabling the production of high-quality synthetic DNA faster, more affordably, and at scale. This platform overcomes conventional inefficiencies, supports cost-effective, high-throughput synthesis, and allows researchers to accelerate innovation. Geographically, the company operates across the Americas, EMEA, and APAC, deriving the majority of its revenue from the Americas.

About HAE Haemonetics Corporation

Haemonetics Corp aims to improve patient care and reduce the cost of healthcare by providing medical products and solutions in the blood and plasma component collection, surgical suite, and hospital transfusion service spaces. As such, the company operates under three segments: plasma, blood center, and hospital. The company primarily emphasizes its plasma and hospital segments due to their robust growth potential, whereas the blood center segment tends to be constrained by higher competition. Product revenue is driven by demand for disposable blood component collection and processing sets and the related equipment needed for proper functionality.

Share on Social Networks: